STOCK TITAN

Apellis Pharmaceuticals, Inc. - APLS STOCK NEWS

Welcome to our dedicated page for Apellis Pharmaceuticals news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmaceuticals stock.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutic compounds. The company's primary focus is on treating diseases with high unmet medical needs through the inhibition of the complement system, a crucial part of the immune system. Apellis targets the complement system at the level of C3, aiming to provide comprehensive disease control.

Apellis's flagship products include SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan). SYFOVRE is the first-ever approved therapy for geographic atrophy (GA), a leading cause of blindness, while EMPAVELI is approved for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare hematological disease. Both medicines reflect the company's innovative approach to complement immunotherapy.

In 2023, Apellis achieved significant milestones, including generating $397 million in revenue, with substantial contributions from SYFOVRE and EMPAVELI. The company has also presented positive data from its Phase 2 NOBLE study for systemic pegcetacoplan in rare kidney diseases at the European Renal Association Congress, highlighting the potential of pegcetacoplan to address complex medical conditions.

Looking ahead, Apellis anticipates regulatory developments, including the European Medicines Agency’s (EMA) review of the marketing authorization application (MAA) for SYFOVRE and the expected topline data from the Phase 3 VALIANT study of systemic pegcetacoplan in mid-2024. Financially robust, Apellis recently closed a $375 million funding deal with Sixth Street to buy out existing liabilities, significantly improving its liquidity profile and positioning the company for sustainable growth.

Apellis's commitment to advancing science is evident through its extensive pipeline and collaborations, such as its partnership with Sobi for systemic pegcetacoplan. The company's approach combines bold scientific endeavors with compassionate patient care, continually striving to bring life-changing therapies to those in need.

Rhea-AI Summary

Apellis Pharmaceuticals, Inc. (APLS) announced positive results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan for geographic atrophy (GA) due to age-related macular degeneration (AMD). In the OAKS study, pegcetacoplan achieved its primary endpoint, reducing GA lesion growth by 22% (p=0.0003) monthly and 16% (p=0.0052) every-other-month. Conversely, DERBY did not meet its primary endpoint, exhibiting lesser reductions. Overall, pegcetacoplan demonstrated a 26% reduction in lesion growth among patients with extrafoveal lesions. Aiming for FDA approval, Apellis plans to submit a New Drug Application in early 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.19%
Tags
-
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced the grant of equity awards to a new employee effective September 1, 2021, as part of their 2021 Inducement Stock Incentive Plan. The awarded equity includes options to purchase 1,000 shares at an exercise price of $64.73, the closing price on the grant date, and 500 restricted stock units (RSUs). The options will vest over four years, while the RSUs will vest annually over four years, contingent on continued employment. This move aims to incentivize talent acquisition in line with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary

On September 3, 2021, Apellis Pharmaceuticals (Nasdaq: APLS) announced the approval of equity awards for Jim Chopas, its newly appointed VP, Corporate Controller / Chief Accounting Officer. The award includes options to purchase 21,750 shares at an exercise price of $65.41, equal to the stock's closing price on the grant date. Additionally, 7,600 restricted stock units (RSUs) were granted. The vesting schedule for both options and RSUs is contingent on Chopas' continued employment with the company. This appointment aligns with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.88%
Tags
none
Rhea-AI Summary

Apellis Pharmaceuticals (APLS) received FDA approval for EMPAVELI™, the first targeted C3 therapy for adults with paroxysmal nocturnal hemoglobinuria (PNH), and initiated a U.S. commercial launch. The company reported $0.6 million in net product revenue for Q2 2021, marking its first sales since EMPAVELI's approval. Additionally, positive results were announced from the Phase 3 PRINCE study, indicating statistical superiority in key endpoints. Apellis continues to expand its pipeline and has entered into a collaboration with Beam Therapeutics for new therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
-
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced on August 6, 2021, that it approved equity awards for three new employees. The awards consist of options to purchase 75,100 shares and 5,050 restricted stock units (RSUs), granted under the 2021 Inducement Stock Incentive Plan. The options have an exercise price of $63.25, equal to the stock's closing price on the grant date. The vesting schedule includes a one-year cliff and monthly vesting thereafter for options, while RSUs vest 25% annually. This move aims to attract talent to support growth and innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
none
-
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) plans to host a conference call and webcast on August 9, 2021, at 4:30 p.m. ET to discuss its second quarter 2021 financial results. Participants can join via phone or through the company’s website. A 90-day replay of the webcast will be accessible post-event. Apellis focuses on targeted C3 therapies and aims to develop transformative treatments for diseases driven by excessive complement activation. More information is available at www.apellis.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences earnings
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) has successfully closed privately negotiated exchange transactions for its 3.500% Convertible Senior Notes due 2026. Approximately $201.1 million of these notes were exchanged, resulting in the issuance of 5,992,217 shares of common stock. The shares are unregistered under current securities laws and cannot be sold in the U.S. without proper registration or exemption. This strategic move aims to strengthen the company's financial position and support its ongoing commitment to developing targeted C3 therapies for various debilitating diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq:APLS) announced it has engaged in privately negotiated exchange agreements with holders of its 3.500% Convertible Senior Notes due 2026. The holders have agreed to exchange approximately $198.6 million of the Notes for 4,530,431 shares of common stock, equating to 22.8065 shares per $1,000 of Notes. An additional number of shares will be issued based on the average stock price over a specified period. The exchange transactions are expected to close by July 23, 2021, pending customary closing conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
-
Rhea-AI Summary

Apellis Pharmaceuticals (APLS) announced equity awards to a new employee, consisting of options for 8,000 shares and 4,000 restricted stock units (RSUs). The options have an exercise price of $67.80, matching the closing stock price on the grant date of July 1, 2021. The vesting schedule sets forth that one-fourth of the options will vest after one year, with the remainder vesting monthly over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and supports the company’s efforts in attracting talent for its targeted C3 therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) and Beam Therapeutics (Nasdaq: BEAM) announced a five-year exclusive collaboration focused on base editing technology to develop treatments for complement-driven diseases. The partnership will target six research programs directed at the eye, liver, and brain, utilizing Beam's technology for precision gene editing. Apellis will lead the development of licensed programs and has committed $75 million, with further milestone payments possible. This strategic alliance aims to enhance Apellis' leadership in complement therapeutics and expand treatment options for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
none

FAQ

What is the current stock price of Apellis Pharmaceuticals (APLS)?

The current stock price of Apellis Pharmaceuticals (APLS) is $33.21 as of December 20, 2024.

What is the market cap of Apellis Pharmaceuticals (APLS)?

The market cap of Apellis Pharmaceuticals (APLS) is approximately 4.1B.

What does Apellis Pharmaceuticals, Inc. specialize in?

Apellis specializes in the discovery, development, and commercialization of novel therapeutic compounds aimed at treating diseases with high unmet medical needs through the inhibition of the complement system.

What are Apellis's primary products?

Apellis's primary products are SYFOVRE® (pegcetacoplan injection) for geographic atrophy and EMPAVELI® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH).

How did Apellis perform financially in 2023?

In 2023, Apellis generated $397 million in revenue, with significant contributions from SYFOVRE and EMPAVELI.

What is SYFOVRE® approved for?

SYFOVRE® is approved for the treatment of geographic atrophy (GA), a leading cause of blindness related to age-related macular degeneration.

What is EMPAVELI® approved for?

EMPAVELI® is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally.

What recent clinical data has Apellis presented?

Apellis recently presented positive data from its Phase 2 NOBLE study for systemic pegcetacoplan in treating C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) at the European Renal Association Congress.

What is the latest financial development for Apellis?

Apellis recently closed a $375 million funding deal with Sixth Street to buy out existing SFJ Pharmaceuticals development liabilities, significantly improving its liquidity profile.

What are Apellis's expectations for 2024?

In 2024, Apellis anticipates regulatory developments from EMA and expects topline data from the Phase 3 VALIANT study for systemic pegcetacoplan in mid-2024.

Who is Apellis collaborating with for systemic pegcetacoplan?

Apellis is collaborating with Sobi for the global co-development and commercialization of systemic pegcetacoplan.

How is Apellis combining science and patient care?

Apellis combines bold scientific endeavors with compassionate patient care, striving to bring life-changing therapies to patients with serious diseases.

Apellis Pharmaceuticals, Inc.

Nasdaq:APLS

APLS Rankings

APLS Stock Data

4.12B
105.50M
13.98%
99.97%
18.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM